Management of sickle cell disease: challenges and risks of transfusion

References

• Nagel RL, Fabry ME, Pagnier J, et al. Hematologically and genetically distinct forms of sickle cell anemia in Africa. The Senegal type and the Benin type. N Engl J Med. 1985;312(14):880–884.
   PubMed Web of Science ®Google Scholar
• Kulozik AE, Wainscoat JS, Serjeant GR, et al. Geographical survey of βS-globin gene haplotypes: evidence for an independent Asian origin of the sickle-cell mutation. Am J Hum Genet. 1986;39(2):239–244.
   PubMed Web of Science ®Google Scholar
• Serjeant G, Serjeant B, Stephens A, et al. Determinants of haemoglobin level in steady-state homozygous sickle cell disease. Br J Haematol. 1996;92(1):143–149.
   Web of Science ®Google Scholar
• Hayes RJ, Beckford M, Grandison Y, Mason K, Serjeant BE, Serjeant GR. The haematology of steady state homozygous sickle cell disease. Frequency distributions, variation with age and sex, longitudinal observations. Br J Haematol. 1985;59(2):369–382.
   PubMed Web of Science ®Google Scholar
• Kar BC, Satapathy RK, Kulozik AE, et al. Sickle cell disease in Orissa State, India. Lancet. 1986;2(8517):1198–1201.
   Web of Science ®Google Scholar
• Bellingham AJ, Huehns ER. Compensation in haemolytic anaemias caused by abnormal haemoglobins. Nature. 1968;218(5145):924–926.
   Web of Science ®Google Scholar
• Badaloo AV, Singhal A, Forrester TE, Serjeant GR, Jackson AA. The effect of splenectomy for hypersplenism on whole body protein turnover, resting metabolic rate and growth in sickle cell disease. Eur J Clin Nutr. 1996;50(10):672–675.
   Web of Science ®Google Scholar
• Emond AM, Collis R, Darvill D, Higgs DR, Maude GH, Serjeant GR. Acute splenic sequestration in homozygous sickle cell disease: natural history and management. J Pediatr. 1985;107(2):201–206.
   PubMed Web of Science ®Google Scholar
• Stevens MCG, Hayes RJ, Vaidya S, Serjeant GR. Fetal hemoglobin and clinical severity of homozygous sickle cell disease in early childhood. J Pediatr. 1981;98(1):37–41.
   PubMed Web of Science ®Google Scholar
• Pearson HA, Cornelius EA, Schwartz AD, Zelson JH, Wolfson SL, Spencer RP. Transfusion reversible functional asplenia in young children with sickle-cell anemia. N Engl J Med. 1970;283(7):334–337.
   Web of Science ®Google Scholar
• Kinney TR, Ware RE, Schultz WH, Filston HC. Long-term management of splenic sequestration in children with sickle cell disease. J Pediatr. 1990;117(2 Pt 1):194–199.
   Web of Science ®Google Scholar
• Rao S, Pang E. Transfusion therapy for subacute splenic sequestration in sickle cell disease. Blood. 1982;60:48a.
   Google Scholar
• Owusu-Ofori S, Remmington T. Splenectomy versus conservative management for acute sequestration crises in people with sickle cell disease. Cochrane Database Syst Rev. 2013;(5):CD003425.
   Google Scholar
• Serjeant GR, Topley JM, Mason K, et al. Outbreak of aplastic crises in sickle cell anaemia associated with parvovirus-like agent. Lancet. 1981;2(8247):595–597.
   PubMed Web of Science ®Google Scholar
• Serjeant BE, Hambleton IR, Kerr S, Kilty CG, Serjeant GR. Haematological response to parvovirus B19 infection in sickle-cell disease. Lancet. 2001;358(9295):1779–1780.
   Web of Science ®Google Scholar
• Wright JG, Hambleton IR, Thomas PW, Duncan ND, Venugopal S, Serjeant GR. Postsplenectomy course in homozygous sickle cell disease. J Pediatr. 1999;134(3):304–309.
   Web of Science ®Google Scholar
• Balkaran B, Char G, Morris JS, Thomas PW, Serjeant BE, Serjeant GR. Stroke in a cohort study of patients with homozygous sickle cell disease. J Pediatr. 1992;120(3):360–366.
   PubMed Web of Science ®Google Scholar
• Powars D, Wilson B, Imbus C, Pegelow C, Allen J. The natural history of stroke in sickle cell disease. Am J Med. 1978;65(3):461–471.
   PubMed Web of Science ®Google Scholar
• Pegelow CH, Adams RJ, McKie V, et al. Risk of recurrent stroke in patients with sickle cell disease treated with erythrocyte transfusions. J Pediatr. 1995;126(6):896–899.
   PubMed Web of Science ®Google Scholar
• Adams RJ, McKie VC, Carl EM, et al. Long-term stroke risk in children with sickle cell disease screened with transcranial Doppler. Ann Neurol. 1997;42(5):699–704.
   PubMed Web of Science ®Google Scholar
• Adams RJ, McKie VC, Hsu L, et al. Prevention of first stroke by transfusions in children with sickle cell anemia and abnormal results on transcranial ultrasonography. N Engl J Med. 1998;339(1):5–11.
   PubMed Web of Science ®Google Scholar
• Lee MT, Piomelli S, Granger S, et al; STOP Study Investigators. Stroke prevention trial in sickle cell anemia (STOP): extended follow-up and final results. Blood. 2006;108(3);847–852.
   Web of Science ®Google Scholar
• DeBaun MR, Gordon M, McKinstry RC, et al. Controlled trial of transfusions for silent cerebral infarcts in sickle cell anemia. N Engl J Med. 2014;371(18):699–710.
   Google Scholar
• Buchanan GR, Bowman WP, Smith SJ. Recurrent cerebral ischemia during hypertransfusion therapy in sickle cell anemia. J Pediatr. 1983;103(6):921–923.
   Web of Science ®Google Scholar
• Wilimas J, Goff JR, Anderson HR Jr, Langston JW, Thompson E. Efficacy of transfusion therapy for one to two years in patients with sickle cell disease and cerebrovascular accidents. J Pediatr. 1980;96(2):205–208.
   Web of Science ®Google Scholar
• Hulbert ML, McKinstry RC, Lacey JL, et al. Silent cerebral infarcts occur despite regular blood transfusion therapy after first strokes in children with sickle cell disease. Blood. 2011;117(3):772–779.
   PubMed Web of Science ®Google Scholar
• Mirre E, Brousse V, Berteloot L, et al. Feasibility and efficacy of chronic transfusion for stroke prevention in children with sickle cell disease. Eur J Haematol. 2010;84(3):259–265.
   PubMed Web of Science ®Google Scholar
• Wang WC, Kovnar EH, Tonkin IL, et al. High risk of recurrent stroke after discontinuance of five to twelve years of transfusion therapy in patients with sickle cell disease. J Pediatr. 1991;118(3):377–382.
   Web of Science ®Google Scholar
• Adams RJ, Brambilla D; Optimizing Primary Stroke Prevention in Sickle Cell Anemia (STOP 2) Trial Investigators. Discontinuing prophylactic transfusions used to prevent stroke in sickle cell disease. N Engl J Med. 2005;353(26):2769–2778.
   PubMed Web of Science ®Google Scholar
• Wayne AS, Schoenike SE, Pegelow CH. Financial analysis of chronic transfusion for stroke prevention in sickle cell disease. Blood. 2000;96(7):2369–2372.
   Web of Science ®Google Scholar
• Lanzkowsky P, Shende A, Karayalcin G, Kim YJ, Aballi A. Partial exchange transfusion in sickle cell anemia. Use in children with serious complications. Am J Dis Child. 1978;132(12):1206–1208.
   Google Scholar
• Davies SC, Luce PJ, Win AA, Rioredan JF, Brozovic M. Acute chest syndrome in sickle-cell disease. Lancet. 1984;1(8367):36–38.
   PubMed Web of Science ®Google Scholar
• Mallouh AA, Asha M. Beneficial effect of blood transfusion in children with sickle cell chest syndrome. Am J Dis Child. 1988;142(2):178–182.
   Google Scholar
• Miller ST, Wright E, Abboud M, et al; STOP Investigators. Impact of chronic transfusion on incidence of pain and acute chest syndrome during the Stroke Prevention Trial (STOP) in sickle-cell anemia. J Pediatr. 2001;139(6):785–789.
   PubMed Web of Science ®Google Scholar
• Koshy M, Burd L, Wallace D, Moawad A, Baron J. Prophylactic red cell transfusions in pregnant patients with sickle cell disease. A randomized cooperative study. N Engl J Med. 1988;319(22):1447–1452.
   PubMed Web of Science ®Google Scholar
• Miller ST, Jensen D, Rao SP. Less intensive long-term transfusion therapy for sickle cell anemia and cerebrovascular accident. J Pediatr. 1992;120(1):54–57.
   PubMed Web of Science ®Google Scholar
• Bentley PG, Howard ER. Surgery in children with homozygous sickle cell anaemia. Ann R Coll Surg Engl. 1979;61(1):55–58.
   Web of Science ®Google Scholar
• Janik J, Seeler RA. Perioperative management of children with sickle cell hemoglobinopathy. J Pediatr Surg. 1980;15(12):117–120.
   Google Scholar
• Fullerton MW, Philippart AI, Sarnaik S, Lusher JM. Perioperative exchange transfusion in sickle cell anemia. J Pediatr Surg. 1981;16(3):297–300.
   Web of Science ®Google Scholar
• Vichinsky EP, Haberkern CM, Neumayr L, et al. A comparison of conservative and aggressive transfusion regimens in the perioperative management of sickle cell disease. The Preoperative Transfusion in Sickle Cell Disease Study Group. N Engl J Med. 1995;333(4):206–213.
   PubMed Web of Science ®Google Scholar
• Homi J, Reynolds J, Skinner A, Hanna W, Serjeant GR. General anaesthesia in sickle-cell disease. Br Med J. 1979;1(6178):1599–1601.
   Google Scholar
• Bischoff RJ, Williamson A 3rd, Dalali MJ, Rice JC, Kerstein MD. Assessment of the use of transfusion therapy perioperatively in patients with hemoglobinopathies. Ann Surg. 1988;207(4):434–438.
   Web of Science ®Google Scholar
• Griffin TC, Buchanan GR. Elective surgery in children with sickle cell disease without preoperative blood transfusion. J Pediatr Surg. 1993;28(5):681–685.
   Web of Science ®Google Scholar
• Howard J, Malfroy M, Llewelyn C, et al. The Transfusion Alternatives Preoperatively in Sickle Cell Disease (TAPS) study: a randomised, controlled, multicentre clinical trial. Lancet. 2013;381(9870):930–938.
   PubMed Web of Science ®Google Scholar
• Spackman E, Sculpher M, Howard J, et al. Cost-effectiveness analysis of preoperative transfusion in patients with sickle cell disease using evidence from the TAPS trial. Eur J Haematol. 2014;92(3):249–255.
   Web of Science ®Google Scholar
• Alotaibi GS, Alsaleh K, Bolster L, McMurtry MS, Wu C. Preoperative transfusion in patients with sickle cell disease to prevent perioperative complications: a systematic review and meta-analysis. Hematology. 2014:19(8):463–471.
   PubMed Web of Science ®Google Scholar
• Spivak M. Sickle-cell anemia complicated by pregnancy. Am J Obstet Gynecol. 1945;50(4):442–446.
   Web of Science ®Google Scholar
• Kobak AJ, Stein PJ, Daro AF. Sickle-cell anemia in pregnancy. A review of the literature and report of six cases. Am J Obstet Gynecol. 1941;41(5):811–821.
   Google Scholar
• Ricks P. Exchange transfusion in sickle cell anemia and pregnancy. Obstet Gynecol. 1965;25:117–119.
   Web of Science ®Google Scholar
• Ricks P Jr. Further experience with exchange transfusion in sickle cell anemia and pregnancy. Am J Obstet Gynecol. 1968;100(8):1087–1091.
   Web of Science ®Google Scholar
• Cunningham FG, Pritchard AJ, Mason R, Chase G. Prophylactic transfusions of normal red blood cells during pregnancies complicated by sickle cell hemoglobinopathies. Am J Obstet Gynecol. 1979;135(7):994–1003.
   Web of Science ®Google Scholar
• Morrison JC, Schneider JM, Whybrew WD, Bucovaz ET, Menzel DM. Prophylactic transfusions in pregnant patients with hemoglobinopathies. Obstet Gynecol. 1980;56(3):274–280.
   PubMed Web of Science ®Google Scholar
• Charache S, Scott JC, Niebyl J, Bonds D. Management of sickle cell disease in pregnant patients. Obstet Gynecol. 1980;55(4):407–410.
   PubMed Web of Science ®Google Scholar
• Miller JM Jr, Horger EO 3rd, Key TC, Walker EM Jr. Management of sickle hemoglobinopathies in pregnant patients. Am J Obstet Gynecol. 1981;141(3):237–241.
   Web of Science ®Google Scholar
• Powars DR, Sandhu M, Niland-Weiss J, Johnson C, Bruce S, Manning PR. Pregnancy in sickle cell disease. Obstet Gynecol. 1986;67(2):217–228.
   PubMed Web of Science ®Google Scholar
• Tuck SM, Brewster EM, Studd JWW, James CE, Pearson TC. Prophylactic blood transfusion in maternal sickle cell syndromes. Br J Obstet Gynaecol. 1987;94(2):121–125.
   Google Scholar
• Asma S, Kozanoglu I, Tarim E, et al. Prophylactic red blood cell exchange may be beneficial in the management of sickle cell disease in pregnancy. Transfusion. 2015;55(1):36–44.
   PubMed Web of Science ®Google Scholar
• Howard RJ, Tuck SM, Pearson TC. Pregnancy in sickle cell disease in the UK: results of a multicentre survey of the effect of prophylactic blood transfusion on maternal and fetal outcome. Br J Obstet Gynaecol. 1995;102(12):947–951.
   PubMedGoogle Scholar
• Okusanya BO, Oladapo OT. Prophylactic versus selective blood transfusion for sickle cell disease in pregnancy. Cochrane Database Syst Rev. 2013;(12):CD010378.
   Google Scholar
• Seeler RA. Intensive transfusion therapy for priapism in boys with sickle cell anemia. J Urol. 1973;110(3):360–361.
   Web of Science ®Google Scholar
• Rifkind S, Waisman J, Thompson R, Goldfinger D. RBC exchange pheresis for priapism in sickle cell disease. JAMA. 1979;242:2317–2318.
   Web of Science ®Google Scholar
• Chernoff AI, Shapleigh JB, Moore CV. Therapy of chronic ulceration of the legs associated with sickle cell anemia. JAMA. 1954;155(17):1487–1491.
   Web of Science ®Google Scholar
• Cohen AR, Martin MB, Silber JH, Kim HC, Ohene-Frempong K, Schwartz E. A modified transfusion program for prevention of stroke in sickle cell disease. Blood. 1992;79(7):1657–1661.
   PubMed Web of Science ®Google Scholar
• Kim HC, Dugan NP, Silber JH, et al. Erythrocytapheresis therapy to reduce iron overload in chronically transfused patients with sickle cell disease. Blood. 1994;83(4):1136–1142.
   Web of Science ®Google Scholar
• Hilliard LM, Williams BF, Lounsbury AE, Howard TH. Erythrocytapheresis limits iron accumulation in chronically transfused sickle cell patients. Am J Hematol. 1998;59(1):28–35.
   Web of Science ®Google Scholar
• Savage WJ, Reddoch S, Wolfe J, Casella JF. Partial manual exchange reduces iron accumulation during chronic red cell transfusion for sickle cell disease. J Pediatr Hematol Oncol. 2013;35(6):434–436.
   Web of Science ®Google Scholar
• Collins AF, Fassos FF, Stobie S, et al. Iron-balance and dose-response studies of the oral chelator 1,2-dimethyl-3-hydro-xypyrid-4-one (L1) in iron loaded patients with sickle cell disease. Blood. 1994;83:2329–2333.
   PubMed Web of Science ®Google Scholar
• Neufeld EJ. Oral chelators deferasirox and deferiprone for transfusional iron overload in thalassemia major: new data, new questions. Blood. 2006;107(9);3436–3441.
   Web of Science ®Google Scholar
• Vichinsky E, Torres M, Minniti CP, et al. Efficacy and safety of deferasirox compared with deferoxamine in sickle cell disease: two-year results including pharmacokinetics and concomitant hydroxyurea. Am J Hematol. 2013;88(12):1068–1073.
   Web of Science ®Google Scholar
• Meerpohl JJ, Schell LK, Rucker G, et al. Deferasirox for managing transfusional iron overload in people with sickle cell disease. Cochrane Database Syst Rev. 2014;5:CD007477.
   Google Scholar
• Vlachaki E, Mainou M, Bekiari E, Vetsiou E, Tsapas A. Safety and efficacy of 4 years of deferasirox treatment for sickle cell disease patients. Hemoglobin. 2013;37(1):94–100.
   PubMed Web of Science ®Google Scholar
• Tsouana E, Kaya B, Gadong N, et al. Deferasirox for iron chelation in multitransfused children with sickle cell disease; long-term experience in the East London clinical hemoglobinopathy network. Eur J Haematol. 2015;94(4):336–342.
   Web of Science ®Google Scholar
• Porter J, Garbowski M. Consequences and management of iron overload in sickle cell disease. Hematology Am Soc Hematol Educ Program. 2013;2013:447–456.
   PubMedGoogle Scholar
• Cox JV, Steane E, Cunningham G, Frenkel EP. Risk of alloimmunization and delayed hemolytic transfusion reactions in patients with sickle cell disease. Arch Intern Med. 1988;148(11):2485–2489.
   Google Scholar
• Vichinsky EP, Earles A, Johnson RA, Hoag MS, Williams A, Lubin B. Alloimmunization in sickle cell anemia and transfusion of racially unmatched blood. N Engl J Med. 1990;322(23):1617–1621.
   PubMed Web of Science ®Google Scholar
• de Montalembert M, Dumont MD, Heilbronner C, et al. Delayed hemolytic transfusion reaction in children with sickle cell disease. Haematologica. 2011;96(6):801–807.
   PubMed Web of Science ®Google Scholar
• Bolton-Maggs PHB, Cohen H. Serious hazards of transfusion (SHOT) hemovigilance and progress is improving transfusion safety. Br J Haematol. 2013;163:303–314.
   PubMed Web of Science ®Google Scholar
• Habibi A, Mekontso-Dessap A, Guillaud C, et al. Delayed hemolytic transfusion reaction in adult sickle-cell disease: presentations, outcomes, and treatments of 99 referral center episodes. Am J Hematol. Epub 2016 Jun 27.
   Google Scholar
• Rosse WF, Gallagher D, Kinney TR, et al. Transfusion and alloimmunization in sickle cell disease. The Cooperative Study of Sickle Cell Disease. Blood. 1990;76(7):1431–1437.
   PubMed Web of Science ®Google Scholar
• Wayne AS, Kevy SV, Nathan DG. Transfusion management of sickle cell disease. Blood. 1993;81(5):1109–1123.
   PubMed Web of Science ®Google Scholar
• Sosler SD, Jilly BJ, Saporito C, Koshy M. A simple, practical model for reducing alloimmunization in patients with sickle cell disease. Am J Hematol. 1993;43(2):103–106.
   Web of Science ®Google Scholar
• Sandler SG, Mallory D, Wolfe JS, Byrne P, Lucas DM. Screening with monoclonal anti-Fy3 to provide blood for phenotype-matched transfusions for patients with sickle cell disease. Transfusion. 1997;37(4):393–397.
   Web of Science ®Google Scholar
• Moreira Júnior G, Bordin JO, Kuroda A, Kerbauy J. Red blood cell alloimmunization in sickle cell disease: the influence of racial and antigenic pattern differences between donors and recipients in Brazil. Am J Hematol. 1996;52(3):197–200.
   Web of Science ®Google Scholar
• Olujohungbe A, Hambleton I, Stephens L, Serjeant B, Serjeant G. Red cell antibodies in patients with homozygous sickle cell disease: a comparison of patients in Jamaica and the United Kingdom. Br J Haematol. 2001;113(3):661–665.
   PubMed Web of Science ®Google Scholar
• Chou ST, Jackson T, Vege S, Smith-Whitley K, Friedman DF, Westhoff CM. High prevalence of red blood cell alloimmunization in sickle cell disease despite transfusion from Rh-matched minority donors. Blood. 2013;122(6):1062–1071.
   PubMed Web of Science ®Google Scholar
• Lasalle-Williams M, Nuss R, Le T, et al. Extended rde blood cell antigen matching for transfusions in sickle cell disease: a review of a 14-year experience from a single center. Transfusion. 2011;51(8):1732–1739.
   PubMed Web of Science ®Google Scholar
• Tahhan HR, Holbrook CT, Braddy LR, Brewer LD, Christie JD. Antigen-matched donor blood in the transfusion management of patients with sickle cell disease. Transfusion. 1994;34(7):562–569.
   Web of Science ®Google Scholar
• Vichinsky EP, Luban NL, Wright E, et al. Prospective RBC phenotype matching in a stroke-prevention trial in sickle cell anemia: a multicenter transfusion trial. Transfusion. 2001;41(9):1086–1092.
   Web of Science ®Google Scholar
• Miller ST, Kim HY, Weiner DL, et al; Investigators of the Sickle Cell Disease Clinical Research Network (SCDCRN). Red blood cell alloimmunization in sickle cell disease: prevalence in 2010. Transfusion. 2013;53(4):704–709.
   PubMed Web of Science ®Google Scholar
• O’Suoji C, Liem RI, Mack AK, Kingsberry P, Ramsey G, Thompson AA. Alloimmunization in sickle cell anemia in the era of extended red cell typing. Pediatr Blood Cancer. 2013;60(9):1487–1491.
   PubMed Web of Science ®Google Scholar
• Chou ST, Liem RI, Thompson AA. Challenges of alloimmunization in patients with hemoglobinopathies. Br J Haematol. 2012;159(4):394–404.
   PubMed Web of Science ®Google Scholar
• Yazdanbakhsh K, Ware RE, Noizat-Pirenne, F. Red blood cell alloimmunization in sickle cell disease: pathophysiology, risk factors, and transfusion management. Blood. 2012;120(3):528–537.
   PubMed Web of Science ®Google Scholar
• Telen MJ, Afenyi-Annan A, Garrett ME, et al. Alloimmunization in sickle cell disease: changing antibody specificities and association with chronic pain and decreased survival. Transfusion. 2015;55(6 Pt 2):1378–1387.
   Web of Science ®Google Scholar
• Allain JP, Assennato SM, Osei EN, et al. Characterization of posttransfusion Plasmodium falciparum infection in semi-immune nonparasitemic patients. Transfusion. Epub 2016 Jun 24.
   Google Scholar
• Holtzclaw A, Mrsic Z, Managbanag J, Calvano T, Colombo C. Transfusion-transmitted malaria not preventable by current blood donor screening guidelines: a case report. Transfusion. Epub 2016 Jun 13.
   Google Scholar
• Abdul-Rauf A, Gauderer M, Chiarucci K. Long-term central venous access in patients with sickle cell disease. Incidence of thrombotic and infectious complications. J Pediatr Hematol Oncol. 1995;17(4):342–345.
   Web of Science ®Google Scholar
• McCready CE, Doughty HA, Pearson TC. Experience with the Port-A-Cath in sickle cell disease. Clin Lab Haematol. 1996;18(2):79–82.
   Google Scholar
• Alkindi S, Matwani S, Al-Maawali A, Al-Maskari B, Pathare A. Complications of PORT-A-CATH® in patients with sickle cell disease. J Infect Public Health. 2012;5(1):57–62.
   Google Scholar
• Shah N, Landi D, Shah R, Rothman J, De Castro LM, Thornburg CD. Complications of implantable venous access devices in patients with sickle cell disease. Am J Hematol. 2012;87(2):224–226.
   PubMed Web of Science ®Google Scholar
• Friedman DF, Lukas MB, Jawad A, Larson PJ, Ohene-Frempong K, Manno CS. Alloimmunization to platelets in heavily transfused patients with sickle cell disease. Blood. 1996;88(8):3216–3222.
   Web of Science ®Google Scholar
• Osaro E, Charles AT. The challenges of meeting the blood transfusion requirements in Sub-Saharan Africa: the need for the development of alternatives to allogenic blood. J Blood Med. 2011;2:7–21.
   PubMedGoogle Scholar
• Anderson R, Cassell M, Mullinax GL, Chaplin H Jr. Effect of normal cells on viscosity of sickle-cell blood: in vitro studies and reports of six years’ experience with a prophylactic program of “partial exchange transfusion”. Arch Intern Med. 1963;111:286–294.
   Google Scholar
• Morrison JC, Wiser WL. The use of prophylactic partial exchange transfusion in pregnancies associated with sickle cell hemoglobinopathies. Obstet Gynecol. 1976;48(5):516–520.
   PubMed Web of Science ®Google Scholar
• Charache S. Treatment of sickle cell anemia. Annu Rev Med. 1981;32:195–206.
   PubMed Web of Science ®Google Scholar
• Kernoff LM, Botha MC, Jacobs P. Exchange transfusion in sickle cell disease using a continuous-flow blood cell separator. Transfusion. 1977;17(3):269–271.
   Web of Science ®Google Scholar
• Kleinman S, Thompson-Breton R, Breen D, Hurvitz C, Goldfinger D. Exchange red blood cell pheresis in a pediatric patient with severe complications of sickle cell anemia. Transfusion. 1981;21(4):443–446.
   Web of Science ®Google Scholar
• Klein HG, Garner RJ, Miller DM, Rosen SL, Statham NJ, Winslow RM. Automated partial exchange transfusion in sickle cell anemia. Transfusion. 1980;20(5):578–584.
   Web of Science ®Google Scholar
• Klein HG. . Cell separators for red cell exchange. In: Scott RB, editor. Advances in the Pathophysiology, Diagnosis and Treatment of Sickle Cell Disease. New York, NY: Alan R Liss; 1982:109–116.
   Google Scholar
• Janes SL, Pocock M, Bishop E, Bevan DH. Automated red cell exchange in sickle cell disease. Br J Haematol. 1997;97(2):256–258.
   Web of Science ®Google Scholar
• White JM, White YS, Buskard N, Gillies ID. Increasing whole blood oxygen affinity during rapid exchange transfusion: a potential hazard. Transfusion. 1976;16(3):232–236.
   Web of Science ®Google Scholar
• Key TC, Horger EO 3rd, Walker EM Jr, Mitchum EN. Automated erythrocytopheresis for sickle cell anemia during pregnancy. Am J Obstet Gynecol. 1980;138(7 Pt 1):731–737.
   Web of Science ®Google Scholar
• Corash LM, Piomelli S, Chen HC, Seaman C, Gross E. Separation of erythrocytes according to age on a simplified density gradient. J Lab Clin Med. 1974;84(1):147–151.
   Web of Science ®Google Scholar
• Propper RD, Button LN, Nathan DG. New approaches to the transfusion management of thalassemia. Blood. 1980;55(1):55–60.
   Web of Science ®Google Scholar
• Serjeant G. Blood transfusion in homozygous sickle cell disease – a cautionary tale. Lancet. 2003;361(9639):1659–1660.
   Google Scholar
• Hankins JS, McCarville MB, Rankine-Mullings A, et al. Prevention of conversion to abnormal transcranial Doppler with hydroxyurea in sickle cell anemia: a Phase III international randomized clinical trial. Am J Hematol. 2015;90(12):1099–1105.
   Web of Science ®Google Scholar
• Ware RE, Davis BR, Schultz WH, et al. Hydroxycarbamide versus chronic transfusion for maintenance of transcranial doppler flow velocities in children with sickle cell anaemia-TCD with transfusions changing to hydroxyurea (TWiTCH): a multicentre, open-label, phase 3, non-inferiority trial. Lancet. 2016;387(10019):661–670.
   PubMed Web of Science ®Google Scholar
• Serjeant GR. Evolving locally appropriate models of care. Ind J Med Res. 2016;143(4):405–413.
   Google Scholar
• Mehta V, Mistry A, Raicha B, Italia Y, Serjeant G. Transfusion in sickle cell disease: experience from a Gujarat centre. Indian J Pediatr. 2014;81(3):234–237.
   Web of Science ®Google Scholar